Osmotic and natriuretic effects might also be less dominant, since SGLT2 inhibitors have little effect on markers of fluid volume overload in patients with HF [17,18,33], and beneficial clinical outcomes are equivalent in HF patients irrespective of whether or not they experienced recent manifestation of volume overload [34]. The gene discussed is SLC5A2; the disease is hydrops fetalis.